The annual conference of the American Society of Clinical Oncology is always the biggest event-making cancer conference. And this year was no different. What caught my attention was a company I’ve discussed before – AstraZeneca (AZN). The company’s lung (Tagrisso) and breast cancer (Enhertu) drugs significantly slowed the spread of disease in two trials, potentially establishing the medicines as the new standard of care for a large number of patients. The positive data — which received a standing ovation at the conference — puts the company on course to ramp up sales of Tagrisso and Enhertu ev…